12:00 AM
 | 
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sonidegib: Additional Phase II data

On secondary endpoints, low-dose sonidegib led to a disease control rate (DCR) of 90.9% in patients with locally advanced BCC and 92.3% in patients with metastatic BCC. High-dose sonidegib led to a DCR of 78.2% in patients with locally advanced BCC and 82.6% in patients with metastatic BCC. Median PFS was 13.1 months in patients with metastatic BCC in the low-dose sonidegib arm and 7.6 months in patients...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >